More articles from Commentary

  • Interpreting the Enhance Trial
    Michael H. Davidson, MD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7) 479-491;

    The impact of the ENHANCE trial reveals more about the political climate than it does about the effects of ezetimibe on the progression of atherosclerosis.

  • Infective endocarditis prophylaxis before dental procedures: New guidelines spark controversy
    Alice Kim, MD and Thomas Keys, MD
    Cleveland Clinic Journal of Medicine February 2008, 75 (2) 89-92;

    Many fewer people will need to receive antibiotics, according to new guidelines released by the American Heart Association.

  • Four no more: The ‘PSA cutoff era’ is over
    J. Stephen Jones, MD and Eric Klein, MD
    Cleveland Clinic Journal of Medicine January 2008, 75 (1) 30-32;

    The prostate-specific antigen (PSA) value is only one of the risk factors for prostate cancer, and no PSA value rules cancer in or out. Therefore, our laboratory reports will no longer list 4.0 μg/L as the upper limit of normal. Instead, we will estimate the patient’s actual risk.

  • Vulnerable patients are between a ‘ROC and a hard place’: Yes, it’s time to screen for coronary artery disease
    Morteza Naghavi, MD and Harvey S. Hecht, MD
    Cleveland Clinic Journal of Medicine October 2007, 74 (10) 757-758;

    In the September 2007 issue, Dr. Michael Lauer rejected the recently proposed Screening for Heart Attack prevention and Education (SHAPE) guidelines. The authors of the SHAPE guidelines would like to address his arguments.

  • The Women’s Health Initiative and hormone therapy, 5 years later
    Susan R. Johnson, MD, MS
    Cleveland Clinic Journal of Medicine October 2007, 74 (10) 755-756;

    “Although I knew then that we were in for a big change, I did not anticipate the total impact.”

  • Listen to the sounds of life
    Elliot H. Philipson, MD
    Cleveland Clinic Journal of Medicine March 2006, 73 (3) 211-212;

    My near-death experience taught me to be thankful for the sounds we can hear and treasure.

  • Malfunctions in implantable cardiac devices: Putting the risk in perspective
    J. David Burkhardt, MD and Bruce L. Wilkoff, MD
    Cleveland Clinic Journal of Medicine September 2005, 72 (9) 736-744;

    A device recall does not call for panic. Physicians should weigh the risks and benefits for the individual patient.

  • The authors reply: Shared appointments can be good care
    David L. Bronson, MD and Richard A. Maxwell, MD
    Cleveland Clinic Journal of Medicine April 2005, 72 (4) 280;

    Shared appointments are not for everybody, but we have found they help in providing access for hopelessly backlogged physicians and are usually enjoyable for both the patients and the physician.

  • ‘Thanks for sharing’: A fictional reflection on shared medical appointments
    Leslie G. Cohen, MD
    Cleveland Clinic Journal of Medicine April 2005, 72 (4) 277-280;

    “I’m not an exhibitionist, Doctor. I came here to see you, not to be part of a medical encounter group.”

  • The sad story of Vioxx, and what we should learn from it
    Juhana Karha, MD and Eric J. Topol, MD
    Cleveland Clinic Journal of Medicine December 2004, 71 (12) 933-939;

    The withdrawal of rofecoxib (Vioxx) has important implications both for patients with arthritis and for the pharmaceutical field in general.

Pages